Literature DB >> 27823691

The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction.

Sofie Aagaard Rerup1, Lia E Bang2, Ulrik M Mogensen2, Thomas Engstrøm2, Erik Jørgensen2, Frants Pedersen2, Christian Torp-Pedersen3, Gunnar Gislason4, Stefan James5, Emil Hagström5, Lars Køber2, Emil L Fosbøl2.   

Abstract

AIMS: Familial hypercholesterolemia (FH) is a common genetic disorder causing accelerated atherosclerosis and premature cardiovascular disease. The aim of this study was to examine the prevalence and prognostic significance of possible FH in patients with myocardial infarction (MI). METHODS AND
RESULTS: By individual-level linkage of data from the Eastern Danish Heart Registry and national administrative registries, a study population of patients referred for coronary angiography due to MI was selected. The study population was divided into "unlikely FH" and "possible FH" based on the Dutch Lipid Clinic Network criteria, which included a plasma low-density lipoprotein cholesterol (LDL-C) and age for onset of cardiac disease. A score of ≥3 points was used as the cutpoint between the 2 groups. Among the study population of 13,174 MI patients, 1,281 (9.7%) had possible FH. These patients were younger (59.1 vs 65.7 years, P ≤ .0001), had similar levels of comorbidities, and were treated more aggressively with cholesterol-lowering drugs compared with patients with unlikely FH. During a median of 3.3 years of follow-up, the unadjusted and adjusted event rates of recurrent MI were higher in patients with possible FH compared with unlikely FH (16% vs 11%, adjusted hazard ratio 1.28, 95% CI 1.09-1.51, P = .003.). Differences in adjusted all-cause mortality were not statistically significant (17% vs 23%, adjusted hazard ratio 0.89 [0.74-1.04], P = .1).
CONCLUSION: We found that MI patients with possible FH have higher risk of recurrent MI but similar risk of mortality compared with unlikely FH patients. Further studies on secondary prevention are warranted.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27823691     DOI: 10.1016/j.ahj.2016.08.001

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  11 in total

1.  Association Between Familial Hypercholesterolemia and Risk of Cardiovascular Events and Death in Different Cohorts: A Meta-Analysis of 1.1 Million Subjects.

Authors:  Yani Yu; Lei Chen; Honghong Zhang; Zihao Fu; Qi Liu; Haijing Zhao; Yuqi Liu; Yundai Chen
Journal:  Front Cardiovasc Med       Date:  2022-06-21

2.  Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease.

Authors:  Leonardo De Luca; Marcello Arca; Pier L Temporelli; Furio Colivicchi; Lucio Gonzini; Donata Lucci; Biagio Bosco; Mariella Callerame; Giulio V Lettica; Andrea Di Lenarda; Michele M Gulizia
Journal:  Clin Cardiol       Date:  2018-08-20       Impact factor: 2.882

3.  Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.

Authors:  Katrina L Ellis; Jing Pang; David Chieng; Damon A Bell; John R Burnett; Carl J Schultz; Graham S Hillis; Gerald F Watts
Journal:  Clin Cardiol       Date:  2018-02-26       Impact factor: 2.882

4.  Familial hypercholesterolemia in Chinese patients with premature ST-segment-elevation myocardial infarction: Prevalence, lipid management and 1-year follow-up.

Authors:  Ranshaka Auckle; Binjie Su; Hailing Li; Siling Xu; Mujin Xie; Yangchun Song; Mohammed Abdul Quddus; Yawei Xu; Ban Liu; Wenliang Che
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

5.  Q192R polymorphism in the PON1 gene and familial hypercholesterolemia in a Saudi population.

Authors:  Khalid Khalaf Alharbi; May Salem Alnbaheen; Fawiziah Khalaf Alharbi; Rana M Hasanato; Imran Ali Khan
Journal:  Ann Saudi Med       Date:  2017 Nov-Dec       Impact factor: 1.526

6.  Prevalence of familial hypercholesterolemia in premature coronary artery disease patients admitted to a tertiary care hospital in North India.

Authors:  J P S Sawhney; Shashi Ranjan Prasad; Manish Sharma; Kushal Madan; A Mohanty; Rajiv Passey; Ashwani Mehta; B Kandpal; Aman Makhija; Rajneesh Jain; R R Mantri; Bhola Shankar Vivek; S C Manchanda; I C Verma
Journal:  Indian Heart J       Date:  2019-01-03

7.  Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey.

Authors:  Hermann Yao; Michel Farnier; Laura Tribouillard; Frédéric Chague; Philippe Brunel; Maud Maza; Damien Brunet; Luc Rochette; Florence Bichat; Yves Cottin; Marianne Zeller
Journal:  Lipids Health Dis       Date:  2021-05-04       Impact factor: 3.876

8.  Familial hypercholesterolemia in very young myocardial infarction.

Authors:  Sha Li; Hui-Wen Zhang; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Xi Zhao; Di Sun; Xiong-Yi Gao; Ying Gao; Yan Zhang; Ping Qing; Xiao-Lin Li; Jing Sun; Geng Liu; Qian Dong; Rui-Xia Xu; Chuan-Jue Cui; Jian-Jun Li
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

9.  Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience.

Authors:  Roberto Scicali; Giorgio Ivan Russo; Marina Di Mauro; Flavia Manuele; Grazia Di Marco; Antonino Di Pino; Viviana Ferrara; Agata Maria Rabuazzo; Salvatore Piro; Giuseppe Morgia; Francesco Purrello
Journal:  J Clin Med       Date:  2020-11-08       Impact factor: 4.241

10.  Familial Hypercholesterolemia Genetic Variations and Long-Term Cardiovascular Outcomes in Patients with Hypercholesterolemia Who Underwent Coronary Angiography.

Authors:  Wen-Jane Lee; Han-Ni Chuang; Yi-Ming Chen; Kae-Woei Liang; Hsin Tung; Jun-Peng Chen; I-Te Lee; Jun-Sing Wang; Ching-Heng Lin; Hsueh-Ju Lin; Wayne Huey-Herng Sheu; Wen-Lieng Lee; Tzu-Hung Hsiao
Journal:  Genes (Basel)       Date:  2021-09-14       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.